{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:03:27Z","timestamp":1787508207560,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370872"],"award-info":[{"award-number":["81370872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.biopha.2017.04.125","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T17:45:42Z","timestamp":1494092742000},"page":"621-631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPAR\u03b1\/AdipoR2, in vivo and in vitro"],"prefix":"10.1016","volume":"91","author":[{"given":"Jing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yancheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 Suppl. 1","key":"10.1016\/j.biopha.2017.04.125_bib0005","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"issue":"46","key":"10.1016\/j.biopha.2017.04.125_bib0010","doi-asserted-by":"crossref","first-page":"12989","DOI":"10.3748\/wjg.v21.i46.12989","article-title":"Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis","volume":"21","author":"Haga","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2017.04.125_bib0020","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2017.04.125_bib0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2017.04.125_bib0030","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0035","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0040","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.biopha.2017.04.125_bib0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2017.04.125_bib0050","first-page":"372","article-title":"Increased risk of cardiovascular disease and chronic kidney disease in NAFLD, Nature reviews","volume":"9","author":"Bonora","year":"2012","journal-title":"Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2017.04.125_bib0055","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.biopha.2017.04.125_bib0060","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.biopha.2017.04.125_bib0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gut.2005.071118","article-title":"Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice","volume":"55","author":"Tomita","year":"2006","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0070","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/jhep.2001.29628","article-title":"Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients","volume":"34","author":"Crespo","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0075","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jhep.2005.09.008","article-title":"Nrf1 gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours","volume":"43","author":"Maurizio","year":"2005","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2017.04.125_bib0080","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3109\/10715762.2013.837577","article-title":"Involvement of free radicals and oxidative stress in NAFLD\/NASH","volume":"47","author":"Sumida","year":"2013","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.biopha.2017.04.125_bib0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2891-2-9","article-title":"Vitamin C and vitamin E in prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in choline deficient diet fed rats","volume":"2","author":"Oliveira","year":"2003","journal-title":"Nutr. J."},{"issue":"9","key":"10.1016\/j.biopha.2017.04.125_bib0090","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.nut.2014.01.016","article-title":"Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis","volume":"30","author":"Ji","year":"2014","journal-title":"Nutrition"},{"key":"10.1016\/j.biopha.2017.04.125_bib0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.biopha.2017.01.028","article-title":"Effects of polyphenol compounds melanin on NAFLD\/NASH prevention","volume":"88","author":"Belemets","year":"2017","journal-title":"Biomed. Pharmacother.=Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2017.04.125_bib0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.biopha.2017.01.114","article-title":"Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice","volume":"88","author":"Jeong","year":"2017","journal-title":"Biomed. Pharmacother.=Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2017.04.125_bib0105","first-page":"1073","article-title":"Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD)","volume":"8","author":"Ni","year":"2016","journal-title":"Am. J. Trans. Res."},{"issue":"3","key":"10.1016\/j.biopha.2017.04.125_bib0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejphar.2011.07.036","article-title":"Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver","volume":"668","author":"Xing","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2017.04.125_bib0115","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.metabol.2015.05.002","article-title":"Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: impact on non-alcoholic fatty liver disease","volume":"64","author":"Ganji","year":"2015","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease","volume":"205","author":"Fruchart","year":"2009","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0125","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2017.04.125_bib0130","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2006.05.054","article-title":"Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance","volume":"131","author":"Tilg","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.biopha.2017.04.125_bib0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nm1557","article-title":"Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions","volume":"13","author":"Yamauchi","year":"2007","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1665-2681(19)30807-5","article-title":"Effects of a low-fat diet on the hepatic expression of adiponectin and its receptors in rats with NAFLD","volume":"14","author":"Ma","year":"2015","journal-title":"Ann. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2017.04.125_bib0145","first-page":"472","article-title":"Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis","volume":"3","author":"Matsunami","year":"2010","journal-title":"In. J. Clin. Exp.Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2017.04.125_bib0150","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.2337\/diabetes.54.12.3358","article-title":"Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination","volume":"54","author":"Tsuchida","year":"2005","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clnu.2013.03.013","article-title":"Wogonin ameliorates hyperglycemia and dyslipidemia via PPARalpha activation in db\/db mice","volume":"33","author":"Bak","year":"2014","journal-title":"Clin. Nutr."},{"issue":"8","key":"10.1016\/j.biopha.2017.04.125_bib0160","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/aps.2015.37","article-title":"Wogonin suppresses osteopontin expression in adipocytes by activating PPARalpha","volume":"36","author":"Zhang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"9","key":"10.1016\/j.biopha.2017.04.125_bib0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5483\/BMBRep.2015.48.9.017","article-title":"baicalein and wogonin inhibits high glucose-induced vascular inflammation in vitro and in vivo","volume":"48","author":"Ku","year":"2015","journal-title":"BMB Rep."},{"key":"10.1016\/j.biopha.2017.04.125_bib0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2016.03.025","article-title":"Wogonin attenuates diabetic cardiomyopathy through its anti-inflammatory and anti-oxidative properties","volume":"428","author":"Khan","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"issue":"45","key":"10.1016\/j.biopha.2017.04.125_bib0175","doi-asserted-by":"crossref","first-page":"72503","DOI":"10.18632\/oncotarget.12700","article-title":"Wogonin prevents TLR4-NF-kappaB-medicated neuro-inflammation and improves retinal ganglion cells survival in retina after optic nerve crush","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"issue":"1\u20133","key":"10.1016\/j.biopha.2017.04.125_bib0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2003.11.064","article-title":"Wogonin inhibits excitotoxic and oxidative neuronal damage in primary cultured rat cortical cells","volume":"485","author":"Cho","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.04.125_bib0185","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.fct.2013.07.022","article-title":"Wogonin attenuates etoposide-induced oxidative DNA damage and apoptosis via suppression of oxidative DNA stress and modulation of OGG1 expression","volume":"59","author":"Attia","year":"2013","journal-title":"Food Chem. Toxicol."},{"issue":"9","key":"10.1016\/j.biopha.2017.04.125_bib0190","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0006-2952(02)01347-3","article-title":"Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi","volume":"64","author":"Hui","year":"2002","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2017.04.125_bib0195","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/hep.26272","article-title":"Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor alpha through a sterol regulatory element-binding protein 1c-dependent mechanism in mice","volume":"58","author":"Wu","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0200","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.biopha.2017.04.125_bib0205","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2017.04.125_bib0210","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.01.003","article-title":"Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis","volume":"52","author":"Akazawa","year":"2010","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2017.04.125_bib0215","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.intimp.2013.08.019","article-title":"Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1\/PI3K\/Akt pathway","volume":"17","author":"Zhang","year":"2013","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2017.04.125_bib0220","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbagen.2013.03.020","article-title":"Biomarkers of lipid peroxidation in clinical material","volume":"1840","author":"Niki","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0225","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1043-2760(01)00411-8","article-title":"The isoprostanes in biology and medicine","volume":"12","author":"Pratico","year":"2001","journal-title":"ABBV Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2017.04.125_bib0230","first-page":"729191","article-title":"Urinary F2-isoprostanes and metabolic markers of fat oxidation","volume":"2015","author":"Il'yasova","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"2","key":"10.1016\/j.biopha.2017.04.125_bib0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0014-5793(95)00649-T","article-title":"Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus","volume":"368","author":"Gopaul","year":"1995","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1743-7075-8-65","article-title":"The intake of high fat diet with different trans fatty acid levels differentially induces oxidative stress and non alcoholic fatty liver disease (NAFLD) in rats","volume":"8","author":"Dhibi","year":"2011","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.biopha.2017.04.125_bib0245","article-title":"Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity","author":"Jorge","year":"2016","journal-title":"Obes. Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0250","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3892\/mmr.2016.5966","article-title":"Inhibition of JNK suppresses autophagy and attenuates insulin resistance in a rat model of nonalcoholic fatty liver disease","volume":"15","author":"Yan","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2017.04.125_bib0255","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.fct.2013.08.036","article-title":"Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease","volume":"63","author":"Li","year":"2014","journal-title":"Food Chem. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0260","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI200420468","article-title":"PPARalpha governs glycerol metabolism","volume":"114","author":"Patsouris","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0265","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/MCB.15.6.3012","article-title":"Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators","volume":"15","author":"Lee","year":"1995","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0270","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2337\/db12-1397","article-title":"Activation of PPARalpha ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress","volume":"62","author":"Chan","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2017.04.125_bib0275","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biopha.2016.11.114","article-title":"Potential involvement of PPAR alpha activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: accuracy of non- invasive panel in determining the stage of liver fibrosis in rats","volume":"85","author":"Hamed","year":"2017","journal-title":"Biomed. Pharmacother.=Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3858\/emm.2009.41.6.045","article-title":"Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice","volume":"41","author":"Jeong","year":"2009","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"10.1016\/j.biopha.2017.04.125_bib0285","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2337\/db15-1565","article-title":"A novel function of hepatic FOG2 in insulin sensitivity and lipid metabolism through PPARalpha","volume":"65","author":"Guo","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.biopha.2017.04.125_bib0290","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2017.04.125_bib0295","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1161\/01.HYP.0000037969.41360.CC","article-title":"PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation","volume":"40","author":"Diep","year":"2002","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.biopha.2017.04.125_bib0300","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/FJC.0b013e31826216ed","article-title":"Clofibrate PPARalpha activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia","volume":"60","author":"Ibarra-Lara","year":"2012","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2017.04.125_bib0305","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cyto.2015.05.031","article-title":"PPARalpha\/gamma agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats","volume":"75","author":"Zhang","year":"2015","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.biopha.2017.04.125_bib0310","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1210\/er.2005-0005","article-title":"Adiponectin and adiponectin receptors","volume":"26","author":"Kadowaki","year":"2005","journal-title":"Endocr. Rev."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333221731140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333221731140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:14:15Z","timestamp":1760094855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333221731140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":62,"alternative-id":["S075333221731140X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.04.125","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPAR\u03b1\/AdipoR2, in vivo and in vitro","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.04.125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}